Ratings BioNTech SE Xetra

Equities

22UA

US09075V1026

Real-time Estimate Tradegate Other stock markets 06:15:14 17/05/2024 pm IST			5-day change	1st Jan Change
85.15 ^EUR	-0.82%		-0.99%	-10.18%

01:43pm	Autolus Therapeutics' Q1 Loss Widens, Licensing Revenue Rises	MT
14/05	Evercore ISI Starts BioNTech With In Line Rating, $100 Price Target	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
The company's share price in relation to its net book value makes it look relatively cheap.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's earnings growth outlook lacks momentum and is a weakness.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
BIONTECH SE	-10.18%	2.24TCr	-
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	11TCr	B+
REGENERON PHARMACEUTICALS, INC.	+10.21%	10TCr	B+
ARGENX SE	+0.38%	2.23TCr	B
GENMAB A/S	-5.57%	1.91TCr	A-
WUXI APPTEC CO., LTD.	-37.36%	1.8TCr	A-
BEIGENE, LTD.	-5.17%	1.79TCr	B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	1.43TCr	C+
SAREPTA THERAPEUTICS, INC.	+37.65%	1.25TCr	C+
LEGEND BIOTECH CORPORATION	-22.94%	845.25Cr	D

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes